Clinical Study to Evaluate the Possible Efficacy and Safety of Minocycline in Patients With Ulcerative Colitis Treated With Mesalamine
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY
Ulcerative colitis (UC) is considered a subcategory of inflammatory bowel disease and the exact cause of ulcerative colitis remains undetermined. the condition appears to be related dysregulated immune response and consequent activation of inflammatory cascades, which are often affected by genetic susceptibility and environmental factors, and 20% to 40% of patients with UC also exhibit extraintestinal manifestations involving the joints, skin, eyes, or hepatobiliary tract
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 60
Healthy Volunteers: f
View:
• Age ≥ 18 years old Both male and female will be included Mild and moderate UC patients diagnosed and confirmed by endoscope Patient treated with 5-aminosalislic acid (mesalamine)
Locations
Other Locations
Egypt
Faculty of Medicine, Mansoura University
RECRUITING
Al Mansurah
Contact Information
Primary
Mostafa Bahaa
mbahaa@horus.edu.eg
+201025538337
Time Frame
Start Date: 2024-01-22
Estimated Completion Date: 2028-08-20
Participants
Target number of participants: 46
Treatments
Active_comparator: control group
control group (Mesalamine group, n =23) who will receive 1 g mesalamine three times daily for 6 months.
Active_comparator: Minocycline group
minocycline group, n = 23) will receive 1 g mesalamine three times daily plus 100 mg minocycline orally twice daily for 6 months.
Related Therapeutic Areas
Sponsors
Leads: Mostafa Bahaa
Collaborators: Amira Fawzy Mohamed Mashaly, Clinical Pharmacy Demonstrator, Faculty of Pharmacy- Horus University, Mounir Hussein Bahgat Internal Medicine Department Mansoura University, Tanta University